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Commentary on: Alcohol Intake Increases High-grade Prostate Cancer Risk Among Men Taking 
Dutasteride in the REDUCE Trial. Fowke JH, Howard L, Andriole GL, Freedland SJ. Eur Urol. 
2014 Feb 9 (E-pub on line) 
______________________________________________________________ 
Stand first 
Two major trials, PCPT and REDUCE, used 5 alpha-reductase inhibitors to determine the 
impact on the subsequent diagnosis of prostate cancer.  Both showed that high alcohol intake 
significantly increased prostate cancer risk among men randomized to the treatment arms. The 
recommendation that patients eliminate alcohol when taking 5 alpha-reductase inhibitors seems 
appropriate. 
_____________________________________________________________ 
Fowke and associates have reviewed data from the Reduction by Dutasteride of Prostate 
Cancer Events (REDUCE) trial relating to alcohol consumption patterns in the study (1). The 
REDUCE trial evaluated the effect of 5 alpha-reductase inhibitor (5-ARI) dutasteride on 
subsequent cancer diagnosis in a group of men with a prior negative biopsy (2). They found that 
alcohol intake was not associated with increased prostate cancer for men in the placebo arm of 
the study, adding support to the fact that alcohol intake is unrelated to prostate cancer risk. 
However, for men on dutasteride, the relationship of alcohol intake and prostate risk was far 
more complex. While alcohol intake was not associated with more low-grade prostate cancer for 
men on dutasteride, increased alcohol intake when combined with dutasteride increased the risk 
of high-grade prostate cancer. Among men randomized to dutasteride or placebo in the 
REDUCE trial, it appears that alcohol consumption negated the protective association between 
dutasteride and high-grade prostate cancer. 
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  The use of alcohol has been associated with increased mortality risk for several cancers 
in men, but only for those with moderate and heavy drinkers based on a meta-analysis by Jin 
and associates (3).  Heavy drinking in this meta-analysis was defined as > 50gm/day with light 
drinking at a level of ≤12.5 g/day being mildly protective of overall mortality. The risk of cancers 
of the oral cavity, larynx, and pharynx rise linearly with alcohol consumption. Heavy drinking is 
also known to be associated with pancreatic and hepatocellular cancers. 
The authors note most cohort and case-control studies report no evidence of an 
association between alcohol use and prostate cancer. Other random studies that draw an 
association have been inconsistent. What is most provocative about this dutasteride based 
study is that the Prostate Cancer Prevention Trial (PCPT) found the highest category of alcohol 
intake was associated with increased risk of both low-grade (Gleason <7) and high-grade 
(Gleason >7) prostate cancer at follow-up biopsy but only among men taking the 5 alpha-
reductase inhibitor finasteride (4). PCPT was also a prostate cancer prevention trial that used 
finasteride as the active agent (5). The findings from PCPT are consistent with the current 
Fowke study. Taken together, this suggests a possible class effect of 5 alpha-reductase 
inhibitors with alcohol interaction possibly increase the risk of prostate cancer. 
A recent review notes that there are no long-term randomized trials of alcohol on overall 
clinical outcomes and alcohol consumption (6). There is strong evidence of causality based 
upon epidemiologic studies and short-term trials that have found beneficial effects of alcohol on 
cardiovascular risk factors with an increased risk of several cancers in men as noted. It remains 
possible that some of the health benefits and risks of alcohol consumption represent 
associations unrelated to the intake of alcohol itself but relate to the interaction between alcohol 
and other modifying factors. This study by Folke and associates adds validity to this observation 
concerning other modifying factors. In this case the 5-alpha reductase inhibitor seems to be 
modifying high grade prostate cancer risk. Other modifying factors on the diagnosis of high 
grade cancer such as statin use have been reviewed in the REDUCE data set. Statins were not 
associated with any prostate cancer including high-grade disease (7). 
This effect of increased prostate cancer risk while on dutasteride is potentially explained 
by several concepts. One focuses on the fact that ethanol metabolism increases oxidative 
stress that may ultimately impact on prostate cancer initiation and progression. Other theories 
relate to hormonal changes such as increased estrogen with heavy alcohol consumption and 
other metabolic changes such as increased insulin levels or folate depletion that create a pro-
carcinogenic effect. It should be noted that these are plausible theories that have not been 
proven. 
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The goal of the Fowke paper was to confirm an association between alcohol 
intake and cancer that was determined in the PCPT trial using data from the REDUCE trial. The 
interaction between alcohol, prostate cancer and 5 alpha reductase inhibitors in these 
retrospective analysis appears to be real. This raises the concern that men taking 5 alpha 
reductase inhibitors for symptomatic benign prostatic hypertrophy might potentially increase the 
risk of prostate cancer. The recommendation by the authors that patients consider elimination of  
alcohol when taking 5α-reductase inhibitors seems appropriate. 
_____________________________________________________________________ 
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